June 7, 2024

Jessica Seo, PharmD, MPH
Designated Federal Officer (DFO), AAC & PCNS
Advisory Committee Management Branch (ACMB), DFO Team 1
Division of Advisory Committee and Consultant Management (DACCM)
Center for Drug Evaluation and Research
Office of Executive Programs
U.S. Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993–0002

Re: FDA-2024-N-1869: Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket

Dear Dr. Seo and PCNS Drugs Advisory Committee members,

This public comment takes no formal position on the supplemental biologics license application for donanemab (BLA 761248) for the treatment of mild cognitive impairment and early dementia due to Alzheimer’s disease (AD), though signatories may take a position in their separate comments. We write with a united voice to urge the Advisory Committee to consider the perspectives of people living with early AD, family and other care partners, researchers, healthcare providers, and advocates as you discuss a traditional FDA approval. We have full confidence in the FDA’s impartial, rigorous, and expert review based on the merits of the Phase 3 data. FDA’s world-class neuroscientists and neurologists are thoroughly equipped and unparalleled in their ability to assess the totality of evidence regarding donanemab.

The development of safe and effective therapies to prevent, delay, slow, and better manage Alzheimer’s disease and related dementia (ADRD) is one of the most pressing and complex public health challenges facing our nation. One in three older adults who die have ADRD, and nearly seven million Americans have dementia due to Alzheimer’s disease.¹

Donanemab does not promise to cure AD or end the scourge of dementia but, if approved by FDA, it would give clinicians and their patients a vitally important
second treatment option with substantial, clinically meaningful benefits to slow the progression of early symptomatic AD. With clear and compelling evidence, donanemab met the primary and all cognitive and functional secondary endpoints in the Phase 3 study. As borne out by the Phase 3 TRAILBLAZER-ALZ-2 (NCT04437511) trial results published in the *Journal of the American Medical Association (JAMA)* last year, donanemab substantially slowed the rate of decline on the integrated Alzheimer Disease Rating Scale (iADRS) and Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) after 18 months of treatment. Donanemab also slowed decline in instrumental activities of daily living (iADL) and multi-domain cognitive impairments of memory, orientation, judgment, and problem-solving. Both the low-medium tau and the high tau trial participants achieved these person-centered therapeutic benefits. Highlighting the urgency and utility of early detection, diagnosis, and treatment, donanemab’s benefits were greatest for people in the earlier pathological stage of disease progression and the extent of benefits (compared to placebo) expanded throughout the trial’s 18-month dosing period.

In short, donanemab’s clinically meaningful effects prolong the real time an individual enjoys their independence and quality of life – time where cognition, personality, and ability to care for oneself remain largely intact – and reduces caregiver burden. We know intuitively and through emerging robust evidence that people living with early symptomatic AD and their care partners believe these quality-of-life attributes are deeply precious and valuable. They hold dear extended quality of life just as much as people living with other serious and life-threatening diseases such as cancer, heart failure, or HIV/AIDS. As more treatments bear positive clinical results, we are optimistic that initial successes catalyze greater advances. The community’s expectations for first generation disease-modifying therapies are measured and the benefit-risk tolerance is reasonable in conjunction with recommended monitoring and management of potential side effects. While additional post-market research on subpopulations that may be especially vulnerable to ARIA is warranted, for the majority of individuals symptomatic ARIA risk is low, and decisions on the appropriateness of treatment with donanemab should be made by individuals in consultation with their physicians. We believe that a just and rational definition of clinical meaningfulness would embrace donanemab’s overall 37% lower risk of progressing to the next clinical stage and (on average) nearly five and half month advantage over placebo in cognitive and functional decline for people living with early symptomatic AD.

Thank you for your consideration of these comments and for FDA’s consistent commitment to illuminating the regulatory pathway for safe and effective products. For any questions or additional information, please contact Ian Kremer, Executive Director of Leaders Engaged on Alzheimer’s Disease (the LEAD Coalition), at ikremer@leadcoalition.org.
Sincerely,

ACCSES – The Voice of Disability Service Providers
Benedit C. Albenisi, PhD, BCMAS, CRQM (Nova Southeastern University*)
Ricardo F. Allegri MD, PhD (School of Medicine, Universidad de Buenos Aires*)
Alliance for Aging Research
Alliance for Patient Access
Michael L. Alosco, PhD (Alzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine*)
Alzheimer's Association
Alzheimer's Disease Resource Center, Inc. (ADRC)
Alzheimer's Drug Discovery Foundation
Alzheimer's Impact Movement (AIM)
Alzheimer's Los Angeles
Alzheimer's New Jersey
Alzheimer's Orange County
Alzheimer's San Diego
Alzheimer's Tennessee
Takashi Amano, PhD, MSW (Rutgers University Newark*)
American Academy of Neurology
American Association for Geriatric Psychiatry
American Brain Coalition
American Federation for Aging Research (AFAR)
American Medical Women's Association
American Society of Consultant Pharmacists (ASCP)
Argentum | Expanding Senior Living
Autistic Women & Nonbinary Network — AWN
Banner Alzheimer's Institute
Banner Health
Barrow Neurological Institute
Beckman Coulter Diagnostics
Andrew R. Bender, Ph.D. (Cleveland Clinic Lou Ruvo Center for Brain Health*)
Benjamin Rose Institute on Aging
Biomarker Collaborative
Soo Borson MD (USC Keck School of Medicine*)
Andrea Bozoki, MD, FAAN (University of North Carolina, Chapel Hill*)
The Brain Donor Project
Brain Injury Alliance of Nebraska
Bridge Builder Strategies
BrightFocus Foundation
Brookdale Senior Living Inc.
Anna D. Burke M.D. (Barrow Neurological Institute, University of Arizona College of Medicine*)
Goldie S. Byrd, PhD (Wake Forest University School of Medicine Maya Angelou Center for Health Equity*)
Danielle Goldfarb Cabral, MD (University of Arizona College of Medicine*)
Ismael Calandri MD (University of Buenos Aires*)

Campaign to Prevent Alzheimer's Disease (PAD 20/20)

Caregiver Action Network

CaringKind, The Heart of Alzheimer's Caregiving

Center for BrainHealth at The University of Texas at Dallas

Center for Healthy Aging

Sandra Bond Chapman, PhD (Center for BrainHealth at The University of Texas at Dallas*)

Joshua Chodosh, MD, MSHS, FACP (NYU Grossman School of Medicine*)

Chronic Disease Coalition

Cleveland Clinic Lou Ruvo Center for Brain Health, Nevada (Andrew Bender)

Carolyn K Clevenger, DNP, GNP-BC, AGPCNP-BC, FAANP, FGSA, FAAN (Emory University*)

Cognitive Dynamics Foundation

Ann D. Cohen, PhD (Department of Psychiatry, University of Pittsburgh, School of Medicine*)

Combined Health Agencies Drive - Nebraska

Jeffrey Cummings, MD, ScD (University of Nevada Las Vegas*)

CurePSP

Danaher Diagnostics

Dementia Alliance International

Dementia Alliance of North Carolina

DigiCARE Realized Inc.

Elizabeth Disbrow, PhD (LSU Health Shreveport Center for Brain Health*)

Easterseals Iowa

The Emory Goizueta Alzheimer's Disease Research Center

Gary Epstein-Lubow, MD (Alpert Medical School of Brown University & Brown University School of Public Health*)

Leslie Chang Evertson, DNP, RN, GNP-BC (UCLA Health Geriatrics*)

Exon 20 Group

5p- Society

Concetta Forchetti MD, PhD (Ascension Center for Cognitive Disorder and Clinical Research*)

Brent P. Forester, MD, MSc (Tufts University School of Medicine*)

Nicole R. Fowler, PhD (Indiana University School of Medicine*)

Giovanni Frisoni, MD (Université de Genève, Department of Rehabilitation & Geriatrics*)

Sam Gandy, MD, PhD (Icahn School of Medicine at Mount Sinai*)

Joseph E. Gaugler, PhD (School of Public Health, University of Minnesota*)

Genetic Alliance

Georgetown University Medical Center Memory Disorders Program

Gerontological Advanced Practice Nurses Association

Laura Gillen, MS (McDaniel College*)

Global Alzheimer's Platform Foundation

Global CEO Initiative on Alzheimer's Disease

Todd Eliot Golde, MD PhD (Emory University, Center for Neurodegenerative Disease*)
Hom Lal Shrestha M.A./PhD (Laurentian University*)
Amanda G. Smith, M.D. (University of South Florida Byrd Alzheimer’s Institute*)
B. Joy Snider, MD, PhD (Washington University School of Medicine*)
Society for Women’s Health Research
Donald Sullivan, MD, MA, MCR (Oregon Health and Science University*)
Pierre N. Tariot, MD (University of Arizona College of Medicine*)
Carmela Tartaglia, M.D., FRCPC (Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto*)
The Association for Frontotemporal Degeneration
Megan Thomas Hebdon, PhD, DNP, RN, NP-c (University of Texas at Austin School of Nursing*)
Tokyo Metropolitan Institute for Geriatrics and Gerontology
Debra F Tomasino, MA, CDP (Grossman School of Medicine, New York University*)
Taisuke Tomita, Ph.D. (The University of Tokyo*)
Toronto Memory Program
Trellis/ACT on Alzheimer’s
R. Scott Turner, MD, PhD (Georgetown University Memory Disorders Program*)

UCLA Mary S. Easton Center for Alzheimer’s Disease Research, David Geffen School of Medicine
UsAgainstAlzheimer’s, LEAD Coalition co-convener
Ipsit Vahia, MD (Mclean Hospital, Harvard Medical School*)
Lawren VandeVrede, MD/PhD (University of California, San Francisco*)
Anand Viswanathan, MD, PhD (Massachusetts General Hospital and Alzheimer’s Disease Research Center*)
Voices of Alzheimer’s
Stella L. Volpe, PhD, RDN, ACSM-CEP, FACSM (Virginia Tech*)
Volunteers of America, LEAD Coalition co-convener
Keith Vossel, MD, MSc (Mary S. Easton Center for Alzheimer’s Disease Research, David Geffen School of Medicine at UCLA)
Wake Forest University School of Medicine Maya Angelou Center for Health Equity
Qing Wang Ph.D. (Washington University in St. Louis, School of Medicine*)
David A. Weidman, MD, FAAN (Banner Alzheimer’s Institute, University of Arizona, College of Medicine*)

* Affiliations of individual researchers are for identification purposes only and do not necessarily represent the endorsement of affiliated institutions.

